29 research outputs found
Prevalência das alterações séricas das enzimas hepáticas e das bilirrubinas em alcoolistas hospitalizados no CDQUIM/RS
Uso de recursos alimentares por peixes imaturos e adultos de espécies piscívoras em uma planície de inundação neotropical
PHP48 Os Motivos Que Levam O JudiciÁrio A Determinar Que Os Planos De SaÚde ForneÇam MedicaÇÃo oral Em Oncologia
PHP35 Perceptions, Knowledge and Gaps about HTA and Health Economics by the Braziian Market Stakeholders: Ispor Brazil Qualitative Research
Prevalência das alterações séricas das enzimas hepáticas e das bilirrubinas em alcoolistas hospitalizados no CDQUIM/RS
PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
von Willebrand factor antigen levels in plasma of patients with malignant breast disease
von Willebrand factor (vWF) is a protein that mediates platelet adherence to the subendothelium during primary hemostasis. High plasma vWF concentrations have been reported in patients with various types of cancer, such as head and neck, laryngeal and prostatic cancer, probably representing an acute phase reactant. In the present study we determined the plasma levels of vWF antigen (vWF:Ag) by quantitative immunoelectrophoresis in 128 female patients with breast cancer as well as in 47 women with benign breast disease and in 27 healthy female controls. The levels of vWF:Ag were 170.7 ± 78 U/dl in patients with cancer, 148.4 ± 59 U/dl in patients with benign disease and 130.6 ± 45 U/dl in controls (P<0.005). We also detected a significant increase in the levels of vWF:Ag (P<0.0001) in patients with advanced stages of the disease (stage IV = 263.3 ± 113 U/dl, stage IIIB = 194.0 ± 44 U/dl) as compared to those with earlier stages of the disease (stage I = 155.3 ± 65 U/dl, stage IIA = 146.9 ± 75 U/dl). In conclusion, vWF levels were increased in plasma of patients with malignant breast disease, and these levels correlated with tumor progression